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Introduction 
Our discipline and our journal cover an extremely broad range of research and scholarly topics 
related to children’s respiratory disorders.  To better meet the needs of our readership for updated 
perspectives on the rapidly expanding knowledge in our field, we will summarize the past year’s 
publications in our major topic areas, as well as selected publications in these areas from the core 
clinical journal literature outside our own pages.  A previous review (Part 1) summarized papers 
published in 2014 relevant to asthma, diagnostic testing/endoscopy, sleep and breathing disorders, 
respiratory complications of neuromuscular disorders, and rare lung diseases.  The current review 
covers articles on neonatal lung disease, pulmonary physiology, and respiratory infection.    
 
Neonatal lung disease and bronchopulmonary dysplasia (BPD) 
BPD pathogenesis, pathophysiology and biomarkers 
There is continued effort to understand the pathophysiology of modern-day BPD in preterm 
infants, which is a predisposing condition to adverse neurodevelopmental outcome as well as life-long 
respiratory system effects.  The relatively wide variation of BPD incidence in NICUs suggests complex 
interaction of host factors and clinical care practices. 
In a large epidemiologic study from the Swedish Birth Register, Eriksson et al.1 reported that 
preeclampsia was a strong risk factor for BPD;  no increased risk was associated with maternal chronic 
inflammatory diseases or use of anti-inflammatory drugs, and maternal diabetes appeared to decrease 
BPD risk.  The authors concluded that impaired angiogenesis may contribute to BPD risk.   Maternal 
factors including diabetes may adversely affect fetal lung development.  In a diabetic rat model, 
Koskinen et al.2 observed that maternal diabetes and hyperoxia combine to induce fetal lung 
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remodeling, delaying alveolarization.  Genetic factors are being explored through genome-wide 
analyses, with some SNPs for known pathways and some novel risk-associated SNPs identified3.   
PH is a significant complication of prematurity and is associated with severe BPD4.  Del Cerro and 
colleagues reviewed the course of pulmonary hypertension in a series of infants with BPD.  At median 
follow-up of 35 months, 22 of 29 patients had been treated with PH drugs, 8 (26%) had died, and there 
was a high incidence (66%) of cardiovascular anomalies including aortopulmonary collaterals, pulmonary 
vein stenosis, and PDA, underscoring the need for definitive diagnosis of the etiology of PH.  One of the 
plausible pathways identified involves angiogenesis, consistent with the so-called ‘vascular hypothesis’ 
of BPD pathogenesis.  Along these lines, Zhang et al.5 reported evidence supporting the predictive value 
of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a widely used marker for pulmonary 
hypertension (PH) in adults,  for readiness for extubation in mechanically ventilated preterm infants, and 
Kalra et al.6 reported that elevated plasma BNP > 24.4 pg/mL at 36 weeks post menstrual age or at 
discharge home was a sensitive marker for BPD.  Effects on the pulmonary vascular system were also 
suggested by Castro et al.7 , who observed that the expression of angiotensin-converting enzyme (ACE) 
in lung endothelium is largely absent from the post-mortem lungs collected from children with BPD. 
Since angiotensin can affect angiogenesis in other systems, the authors speculate that lack of ACE 
expression could contribute to  the development of BPD. 
Oxidative stress is thought to be a common pathway mediating alveolar and vascular lung 
damage in preterm infants exposed to hyperoxia. In order to determine if  limiting initial oxygen 
exposure could be done safely,  investigators conducted a randomized trial of initial oxygen treatment 
(FIO2 = 35% v. 60%) during resuscitation of preterm infants, and found no impact on BPD8.  In a preterm 
lamb model, combining surfactant with antioxidants superoxide dismutase and catalase mitigated tissue 
oxidative stress9.  Oxidative stress and hypoxia contribute to pulmonary vascular remodeling, a feature 
common to both persistent pulmonary hypertension of the newborn and PH that complicates BPD. 
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Awad et al.10 showed that  hypoxia-induced catalase expression pathways in pulmonary artery smooth 
muscle cells is insufficient to protect pulmonary artery smooth muscle cells from hypoxia-induced lipid 
peroxidation.  In an experimental rat model study, microRNA 26-a was noted to regulate surfactant 
protein expression by type II airway epithelial cells11.   
Pulmonary hypoplasia is typically complicated by PH, and is associated with high perinatal 
mortality.  Its clinical diagnosis relies on relatively imprecise measures of lung expansion obtained by 
radiography as well as assessments of lung mechanics. At autopsy, the ratio of lung weight to body 
weight is typically used, but this measurement may be confounded by intra-alveolar lung liquid.   De 
Paepe et al.12 measured postmortem lung volumes, which would be unaffected by alveolar edema, and 
body weights in preterm and term infants at risk for pulmonary hypoplasia, and were able to determine 
age-specific lung volume/body weight reference values.   
 
Prevention and treatment of BPD and neonatal lung disorders 
Specific treatments or prevention strategies for BPD have been elusive.  Wide variation in BPD 
incidence suggests multiple factors at play.   Since mechanical ventilation is one such factor, 
investigators have pursued less invasive administration of treatments previously administered 
exclusively via the endotracheal route.  In a randomized multicenter trial, inhaled nitric oxide in non-
intubated preterm infants was safe but did not significantly reduce BPD risk13.  However, combination of 
inhaled NO with vitamin A supplementation did have significant benefit14.   
Since pulmonary hypoplasia has been implicated in severe BPD, investigators have pursued cell-
based therapies using progenitor cells that have yielded promising results in animal models, apparently 
via paracrine effects (see 15 for review ).  In this same vein, a phase I trial of intratracheal allogeneic 
human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation in a small 
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group of 25-week gestation preterm infants yielded lower markers of inflammation and reduced BPD 
severity16.  Anti-inflammatory treatment with corticosteroids is known to have a beneficial effect on the 
course of lung disease in preterm infants at risk for BPD, but is associated with significant side effects 
which limit use.  Masood et al.17 used a selective COX-2 inhibitor in neonatal rats to prevent neutrophil 
influx and reduce hyperoxia-induced lung injury, suggesting that non-steroid anti-inflammatory 
approaches - e.g., chemokine, chemokine receptor blockade - may be useful, as has been previously 
demonstrated by this research group and others who have targeted neutrophil and macrophage influx 
using similar model systems.  Kahveci et al.18 reported their retrospective experience with the 
prostacyclin analog inhaled iloprost, and sildenafil, in treatment of PPHN.  They found that treatment 
with iloprost achieved a more rapid response and avoided systemic hypotension.  The authors 
hypothesize that iloprost is safer and more effective (time to clinical response, duration of mechanical 
ventilation) than sildenafil, but this conclusion will require a direct comparison in a randomized, 
controlled trial.   
The optimal timing and less-invasive methods of delivery of surfactant to preterm newborns are 
ongoing areas of investigation19.  Minocchieri et al.20 reported a series of aerosol experiments suggesting 
that nebulization of surfactant (vs. conventional direct instillation) may be a viable alternative, based on 
the physical characteristics of the nebulized material.  The routine use of surfactant itself has come into 
question recently.  The American Academy of Pediatrics Committee on the fetus and newborn published 
a policy statement indicating that continuous positive airway pressure started at or soon after birth with 
subsequent selective surfactant administration may be considered as an alternative to routine 
intubation with prophylactic or early surfactant administration in preterm infants21.   
Volume-targeted ventilation was found in a meta-analysis to reduce BPD risk and other 
complications of premature birth, compared to pressure-limited ventilation strategies22. Noninvasive 
ventilation techniques are of increasing interest in neonatal medicine and may reduce BPD risk 
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compared to intubation with mechanical ventilation23.  Stern et al.24 reported a pilot clinical study to test 
the performance of bi-level nasal CPAP coupled with the Graseby capsule, a pneumatic device designed 
to detect infant breathing movements.  They found that subxiphoid capsule placement achieved the 
best synchrony with respiratory movements.  Shi et al.25 reported a randomized controlled trial in which 
infants with RDS were supported with nasal intermittent positive pressure ventilation (NIPPV) vs. nasal 
CPAP; significantly fewer NIPPV treated infants (11%) required intubation and mechanical ventilation, 
compared to NCPAP (21%). 
Placement of gastrostomy tubes (GT) (with or without Nissen fundoplication) to promote 
growth, address feeding difficulties, or limit pulmonary aspiration is common in infants with BPD.  
Recently, non-invasive oral-motor interventions have been assessed to determine if they can 
successfully address feeding problems.  In order to determine the benefit of GT ± Nissen fundoplication 
on outcomes in children with BPD, McGrath-Morrow and colleagues conducted a retrospective review 
of 398 infants with BPD.  They reported that infants with GT were more likely to have birth weights <10 
%ile, to be discharged on supplemental oxygen, and to have more rehospitalizations, but no difference 
in signs of respiratory difficulty, according to caregiver questionnaire, than comparable BPD infants 
without GT26.   As the authors pointed out, it cannot be determined that GT placement had any effect on 
BPD recovery in this retrospective analysis. 
 
Pulmonary physiology 
 Race and ethnicity impact spirometric indices and interpretation of this data; therefore, 
choosing proper reference equations is critical.  An interesting report by Wolff and colleagues27 
describes spirometry data in a population of normal children in Madagascar, who have diminished 
forced vital capacity (FVC) and forced expired volume in 1 second (FEV1) compared to European28 and 
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African29 reference data.  The authors speculate that genetic, environmental and socioeconomic factors 
may explain these differences.  The GLI-2012 reference equations represent international data from 
Caucasians,  African Americans and Asians,  thus may not be appropriate for the African population. 
Given this, reference data such as those generated by Wolff and colleagues are important.   Quanjer and 
Weiner30 compared the interpretation of spirometry data, in a clinically and racially heterogeneous 
patient population at Children’s Hospital of Pittsburgh, using the GLI-2012 prediction equations, 
compared to other published reference equations.   Interpretation of the results was comparable 
between GLI-2012 and Wang and Hankinson references.  However, interpretation differed when 
compared to Knudson, Polgar, or Zapletal.  Hoo et al.31 reported that both full term and premature 
nonwhite infants had lower forced expired volume at 0.5 seconds (FEV0.5) and FVC at 12 months post-
term age compared to white infants, highlighting the importance of ethnicity in interpretation of infant 
lung function as well as that in older children.  Further, FEV0.5 and forced expiratory flows in the 
extremely premature infants were diminished compared to preterm controls and this finding was more 
prevalent in those with bronchopulmonary dysplasia. 
 Lodge et al.32 reported data from the Melbourne Atopy Cohort Study to shed further light on 
lung function sequelae of early childhood wheezing phenotypes.  In children at high risk for allergy 
followed from birth, persistent wheeze phenotypes in childhood were associated with reduced FEV1 
values through adolescence.  Intermediate-onset wheezers showed irreversible airflow limitation by 18 
years, while early transient wheeze had no respiratory health sequelae by age 18. 
  Infant lung function (ILF) testing, while providing key data for clinical research, has had variable 
usage for clinical purposes.  In a survey of international ILF practices, Peterson-Carmichael et al.33 
reported  that ILF is less commonly used for clinical management in North America than in Europe and 
other continents.  The need for sedation and time intensive nature of the testing were cited as factors 
limiting use.  Using the Copenhagen Prospective Study on Asthma in Childhood 2000 birth cohort, 
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Kreiner-Moller et al.34 studied the association of genetic variants previously associated with low lung 
function in adults, with infant lung function (raised-volume thoracoabdominal compression technique) 
and lung function development until age 7 years.  There was no association of these genetic variants 
with lung function at 1 month, but a genetic variant associated with lung function in adults was 
associated with reduced forced expiratory flows at 50% of FVC (FEF50) at 7 years of age and with 
increased bronchial responsiveness at age 7 years, suggesting that there is a window of opportunity for 
interventions targeting these genetic factors in early childhood.   
Alternative, less effort-dependent lung function testing modalities in children are being refined.  
The multiple breath washout technique, a tidal breathing measure that uses an inert gas to assess 
ventilation inhomogeneity, has been shown to be sensitive to early disease in cystic fibrosis, and 
European Respiratory Society/American Thoracic Society guidelines were published in 2013 for the 
school age child35. Coutier and colleagues36 compared results of specific airway resistance (sRaw) testing 
using the panting method compared to  the tidal breathing method, in school age children;  the panting 
method appeared to be more reliable.  An interesting study used electric impedance tomography to 
assess ventilation distribution in spontaneously breathing infants and children. Findings revealed 
variability in the relationship between dependency and relative ventilation37.   This challenges the 
dogma that non-dependent lung regions are better ventilated in children.  
 Lung function in specific disease or high-risk populations may be relevant for prognosis and 
clinical care.   Lin et al.38 described spirometry results in 35 children with mucopolysaccharidoses, 
showing that the majority had evidence for small airway obstruction, and about half had evidence of 
restriction.  Chest CT scans were reported to correlate with lung function abnormalities in pediatric 
sarcoidosis patients; thereby, potentially allowing a reduction in the number of CT scans required for 
follow-up39.  In healthy adolescents, obesity was reported to be associated with lung function 
abnormalities, with a negative relationship between BMI and percent predicted functional residual 
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capacity (FRC), residual volume (RV), and FEV1/FVC 40.  Diminished lung volumes occurred in those with 
elevated BMI, and adiposity measures included body mass index (BMI), percent body fat (PBF), and 
waist circumference (WC).  Forno et al.41 showed links among these adiposity measures, atopy, asthma 
control, and lung function changes in Puerto Rican asthmatics.  Prenatal bisphenol A exposure, a 
prevalent endocrine disrupter, was demonstrated to be linked to wheezing and reduced FEV1 at age 4 
years in a birth cohort study42.   
Prognostically and therapeutically important physiologic data may be obtained in children with 
neuromuscular disorders.  Felix et al. 43 reported that inspiratory muscle training in children with ataxia 
telangiectasia (A-T), a genetic disorder involving neuromuscular weakness and impaired cough, resulted 
in significant improvements in both lung volume and quality of life.  In another retrospective report on 
children with A-T, the majority of patients less than 15 years of age who died of respiratory causes had 
S. aureus, S. Pneumoniae, or H. influenzae cultured from respiratory secretions; while older patients had 
a high prevalence of P. aeruginosa44.  To achieve lung volume recruitment in patients with 
neuromuscular weakness, voluntary breath stacking has been a useful technique.  Jenkins et al.45 
reported a careful study of the effects of involuntary breath stacking maneuver in 6 children with 
muscular dystrophy, and documented improvements in minute ventilation, suggesting that this 
technique might be useful in children unable to voluntarily cooperate.   Finkel and colleagues46 provided 
striking data demonstrating the feasibility and safety of testing respiratory muscle strength in infants 
with spinal muscular atrophy type I. 
 
Respiratory infection 
While overall there has been progress in reducing childhood mortality worldwide, pneumonia 
remains the major cause of death in young children outside the neonatal period, especially in sub-
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Saharan Africa and Asia47.   Agweyu et al. reported that oral amoxicillin is not inferior to i.v. penicillin in 
the treatment of children age 2-59 months with WHO-defined severe pneumonia.   
Respiratory manifestations of HIV infection are an important issue and were addressed in 
several important studies.  In low- and middle-income countries, HIV infection continues to be a major 
risk factor for childhood pneumonia48.  Theodoratu et al.49 reviewed studies of pneumonia in HIV-
infected children, highlighting the disproportionately high risk in this population.  Pitcher and 
colleagues50 reported a prospective study of 330 HIV-infected children in South Africa, in which chest x-
ray findings were correlated with clinical and immunologic factors.  More severe x-ray findings including 
confluent opacifications and nodules were associated with a 7-fold odds ratio for advanced clinical HIV 
disease.    
  Inequity in health outcomes is a major issue in children with chronic lung diseases.   Singleton 
et al.51 reported a study of factors associated with increased risk for chronic suppurative lung disease 
(CSLD), including bronchiectasis, among indigenous children from Australia, the US, and New Zealand.  
Like the overall indigenous population, these children had poor housing and socioeconomic status;  but 
household crowding, prematurity and a history of early acute lower respiratory infections were 
associated with CSLD.  Addressing these factors may help reduce CSLD in these at-risk children.  In an 
interesting study comparing quality of life and other factors between CSLD and CF patients, Nathan et 
al.52 concluded that growth outcomes and parental mental health are actually worse in children with 
CSLD than children with CF.    
The investigation of aerosolized antibiotics for treatment of respiratory infection has continued, 
and the physicochemical effects on drugs of aerosolization are critical to understand.  Kamalaporn et al. 
53 reported an in vitro study in which nebulization of liposomal amphotericin B did not disrupt 
liposomes, which were promising results for its eventual use in children with Aspergillosis and other 
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fungal infections.  Acinetobacter  was treated successfully with inhaled colistin monotherapy (34 mg 
twice daily for an average of 9 days) in 8 premature infants  in a report from Kang et al.54  The infants 
ranged in age from 33-103 days, and in weight from 1470 to 3840 grams, and none had renal toxicity.   
The description of cough (wet vs. dry) may have implications for infection risk.  Wurzel et al.55 
prospectively studied BALF characteristics among children undergoing bronchoscopy for cough, and 
those with wet cough had higher BALF neutrophilia and bacterial and viral infection than those with dry 
cough.   
Honkinen et al.56 provided long-term imaging (MRI) and functional followup of 26 children with 
empyema.  While spirometry was normal in 80%, 92% had MRI abnormalities, mostly pleural scarring, 
though the physiologic significance may be minor.  Differentiating bacterial from viral pneumonia for 
purposes of decisions about antibiotics is challenging.  Torres et al.57 carried out a trial in which children 
age 3-60 months with acute pneumonia in an outpatient setting were randomized to routine 
management vs. use of a bacterial pneumonia predictive score.  The group managed according to the 
standardized score received less antibiotics, but the clinical outcomes did not differ between groups.    
Respiratory syncytial virus (RSV) continues to be a prominent and costly cause of acute lower 
respiratory illness in children worldwide58.  A household cohort study that used molecular RSV 
diagnostics revealed that school-going children in a household are the major source of infant RSV 
infection 59. Rodriguez et al.60 reported that risk factors for severe RSV disease in Colombia include age < 
6 months, prematurity, congenital heart disease, and mixed RSV-adenovirus infection.   A meta-analysis 
of studies assessing relation between vitamin D receptor polymorphisms and acute RSV bronchiolitis 
yielded only 3 eligible studies, but all three suggested a significant association between the Fokl allele 
and severe disease61.  In treating RSV bronchiolitis, the use of epinephrine, albuterol and corticosteroids 
may be decreasing, but only modestly, following publication of practice guidelines highlighting lack of 
effectiveness of these agents62 .  The use of palivizumab in children with chronic lung conditions other 
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than prematurity  remains a topic of debate, due to the paucity of controlled trials.  Gaboli et al.63 
reported a Delphi study involving 48 Spanish experts, in which expert consensus favored the use of  
palivizumab in children up to 12-24 months of age with neuromuscular weakness, CF, ciliary disorders, 
tracheoesophageal atresia, bronchopulmonary malformations, and lung transplant recipients.  
Comparing acute and convalescent sera, Sande et al.64 show that neutralizing antibody titers to RSV only 
rise if infants were 4 months or older at the time of natural RSV infection, suggesting that live RSV 
vaccination will not be effective before 4 months of age and that maternal vaccination will be required 
to protect very young infants.  
 Tuberculosis (TB) continues to be a worldwide problem.  Walters et al.65 reported data from a 
small series of children with complicated TB, in some of whom the addition of rapid PCR-based testing of 
BALF for M. tuberculosis gave added information of therapeutic importance.  Garazzino et al.66 reported 
a series of 9 pediatric patients age 6 months to 13 years, who were treated with moxifloxacin 10 
mg/kg/day as part of an anti-TB multiple drug regimen.   Clinical outcomes were good, and one patient 
(age 6 years) developed arthritis, and another (age 3 years) had liver toxicity.   One of the potential 
complications of pulmonary tuberculosis (TB) in children is compression of central airways by enlarged 
mediastinal lymph nodes.  Andronikou and co-authors67 hypothesized, based on a study of CT findings in 
children with TB, that mediastinal shift from right lung volume loss is associated with compression of the 
left main stem bronchus  due to narrowing of the pulmonary artery bifurcation angle. 
 Mycoplasma pneumoniae is a common acute infection in Chinese children, and in some cases is 
refractory to macrolide treatment.  In a randomized controlled trial, children with refractory 
mycoplasma received either intravenous azithromycin (10 mg/kg/day) alone or azithromycin plus oral 
prednisolone (2 mg/kg/day) for 5 days68.   Clinical outcomes of dyspnea, resolution of radiographic 
changes, duration of hypoxemia, and fever were all better in the corticosteroid group.   
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